DK1616184T3 - Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse - Google Patents

Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse

Info

Publication number
DK1616184T3
DK1616184T3 DK04758356T DK04758356T DK1616184T3 DK 1616184 T3 DK1616184 T3 DK 1616184T3 DK 04758356 T DK04758356 T DK 04758356T DK 04758356 T DK04758356 T DK 04758356T DK 1616184 T3 DK1616184 T3 DK 1616184T3
Authority
DK
Denmark
Prior art keywords
ngal
renal
kit
cell injury
early onset
Prior art date
Application number
DK04758356T
Other languages
English (en)
Other versions
DK1616184T4 (da
Inventor
Prased Devarajan
Jonathan M Barasch
Original Assignee
Childrens Hosp Medical Center
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135089&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1616184(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hosp Medical Center, Univ Columbia filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of DK1616184T3 publication Critical patent/DK1616184T3/da
Publication of DK1616184T4 publication Critical patent/DK1616184T4/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04758356.2T 2003-03-27 2004-03-26 Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse DK1616184T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45814303P 2003-03-27 2003-03-27
US48159603P 2003-11-04 2003-11-04
PCT/US2004/009191 WO2004088276A2 (en) 2003-03-27 2004-03-26 A method and kit for detecting the early onset of renal tubular cell injury

Publications (2)

Publication Number Publication Date
DK1616184T3 true DK1616184T3 (da) 2009-10-19
DK1616184T4 DK1616184T4 (da) 2018-08-13

Family

ID=33135089

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04758356.2T DK1616184T4 (da) 2003-03-27 2004-03-26 Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse
DK10183320.0T DK2360475T3 (da) 2003-03-27 2004-03-26 Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10183320.0T DK2360475T3 (da) 2003-03-27 2004-03-26 Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade

Country Status (14)

Country Link
US (11) US20040219603A1 (da)
EP (3) EP2083270B1 (da)
JP (2) JP5392980B2 (da)
CN (1) CN102183656B (da)
AT (1) ATE437371T1 (da)
AU (1) AU2004225472B2 (da)
BR (1) BRPI0408802B8 (da)
CA (1) CA2520658A1 (da)
DE (1) DE602004022150D1 (da)
DK (2) DK1616184T4 (da)
ES (3) ES2330005T5 (da)
MX (1) MXPA05010385A (da)
NZ (1) NZ543028A (da)
WO (1) WO2004088276A2 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1169702A (en) 2000-10-13 2002-04-22 Childrens Medical Center Non-invasive enzyme screen for tissue remodelling-associated conditions
JP5392980B2 (ja) * 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター 早発型の腎尿細管細胞障害を検出するための方法およびキット
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2005107793A2 (en) * 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
PL1831699T3 (pl) * 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7858324B2 (en) * 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US20100062537A1 (en) * 2005-11-30 2010-03-11 Harald Mischak Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO)
ES2352801T3 (es) * 2005-12-22 2011-02-23 Kiacta Sàrl Tratamiento de nefropatía diabética.
WO2007098102A2 (en) 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20090197280A1 (en) 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
EP2064553B2 (en) † 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
GB0617429D0 (en) * 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
MX2009006768A (es) * 2006-12-22 2009-08-31 Bellus Health Int Ltd Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
EP2137538B1 (en) 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2479571A3 (en) * 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
WO2009062520A1 (en) * 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
US8592170B2 (en) 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
US20090238812A1 (en) 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
US20090239242A1 (en) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early identification and prediction of kidney injury
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
US20120083421A1 (en) * 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010054025A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
CA2744434C (en) * 2008-11-21 2017-10-03 Phadia Ab Methods, devices and kits for detecting or monitoring acute kidney injury
CN102300875B (zh) * 2009-01-28 2014-07-16 财团法人工业技术研究院 肾病相关的生物标记
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
CA2766228A1 (en) * 2009-07-02 2011-01-06 Mosaiques Diagnostics And Therapeutics Ag Process and markers for the diagnosis of acute renal failure
JP5775874B2 (ja) * 2009-08-28 2015-09-09 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605561A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105137085A (zh) * 2010-06-23 2015-12-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012068545A1 (en) * 2010-11-18 2012-05-24 Jonathan Barasch Ngal in acute kidney injury
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
US9387031B2 (en) * 2011-07-29 2016-07-12 Medtronic Ablation Frontiers Llc Mesh-overlayed ablation and mapping device
ES2721907T3 (es) 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3736570A1 (en) 2019-05-09 2020-11-11 Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León Method for the diagnosis, sub-classification and prognosis of acute kidney injury by detecting cct7
CN112076309A (zh) * 2020-07-27 2020-12-15 南通大学 一种环状促红素衍生肽在肾损伤和环孢素a损伤保护中的应用
US20230384323A1 (en) * 2020-10-16 2023-11-30 Lmx Medtech Llc Method for Correction for Sample Volume
CN113083264A (zh) * 2021-04-16 2021-07-09 郑州大学 二氧化硅-金属有机骨架核壳型复合材料及其在硫醇小分子检测方面的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4731326A (en) * 1984-06-04 1988-03-15 Ortho Diagnostic Systems Inc. Disease diagnosis by detection of shed normal tissue antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
IL85257A (en) * 1987-02-10 1993-02-21 Tanabe Seiyaku Co Pharmaceutical compositions containing 2-(4-methoxyphenyl) 3-acetoxy-5-- (2-(dimethylamino) ethyl) -8-chloro-2,3- dihydro-1,5-benzothiazepin -4 (5h)-one having renal function-improving effect and diuretic effect
US4900662A (en) * 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US4870007A (en) 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5358850A (en) * 1992-06-19 1994-10-25 Shionogi Seiyaku Kabushiki Kaisha Sandwich immunoassay of β-n-acetylglucosaminidase and monoclonal antibody used therein
SE9401351D0 (sv) * 1994-04-21 1994-04-21 Venge A method for diagnosis
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
EP0864086A4 (en) * 1995-10-02 2001-05-02 Univ Columbia BIOCHEMICAL MARKERS OF THE ISCHEMY
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
EA004402B1 (ru) * 1996-05-24 2004-04-29 Байоджен, Инк. Модуляторы регенерации тканей
US5945294A (en) * 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
JP3334558B2 (ja) * 1997-04-23 2002-10-15 富士レビオ株式会社 酵素免疫測定方法及び試験片
KR100546223B1 (ko) * 1997-04-30 2006-01-26 마루하 주식회사 허혈성질환의 검출 또는 예지방법과 그 검출용키트
US6020163A (en) * 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
WO2000078919A1 (en) * 1999-06-18 2000-12-28 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
US20020160495A1 (en) * 2000-09-20 2002-10-31 University Of Medicine And Dentistry Soluble ischemia activated protein
AU2001293964B2 (en) * 2000-10-03 2007-06-14 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
AU1169702A (en) * 2000-10-13 2002-04-22 Childrens Medical Center Non-invasive enzyme screen for tissue remodelling-associated conditions
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
AU2002305394A1 (en) * 2001-05-04 2002-11-18 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
EP1390497A2 (en) * 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
AU2003247303A1 (en) * 2002-07-17 2004-02-02 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
CN1220487C (zh) * 2003-03-26 2005-09-28 浙江大学 复方肾保护氨基酸组合物及其应用
JP5392980B2 (ja) * 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター 早発型の腎尿細管細胞障害を検出するための方法およびキット
PL1831699T3 (pl) * 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions

Also Published As

Publication number Publication date
NZ543028A (en) 2008-06-30
DK2360475T3 (da) 2020-01-06
US20130137191A1 (en) 2013-05-30
EP2083270A1 (en) 2009-07-29
DK1616184T4 (da) 2018-08-13
WO2004088276A2 (en) 2004-10-14
AU2004225472B2 (en) 2011-02-10
CN102183656B (zh) 2014-04-16
ES2739463T3 (es) 2020-01-31
EP2360475B1 (en) 2019-10-02
DE602004022150D1 (de) 2009-09-03
MXPA05010385A (es) 2006-03-08
EP1616184B1 (en) 2009-07-22
ES2330005T3 (es) 2009-12-03
US20100233728A1 (en) 2010-09-16
US20120028371A1 (en) 2012-02-02
EP1616184A4 (en) 2006-07-12
CA2520658A1 (en) 2004-10-14
JP2006521565A (ja) 2006-09-21
WO2004088276A3 (en) 2004-11-25
US20150185231A1 (en) 2015-07-02
BRPI0408802B8 (pt) 2021-07-27
US20130183693A1 (en) 2013-07-18
US20070254370A1 (en) 2007-11-01
ATE437371T1 (de) 2009-08-15
US20090181407A1 (en) 2009-07-16
JP2011221033A (ja) 2011-11-04
US20100227418A1 (en) 2010-09-09
US20130137116A1 (en) 2013-05-30
BRPI0408802A (pt) 2006-04-04
EP2083270B1 (en) 2019-06-12
US20040219603A1 (en) 2004-11-04
EP1616184B2 (en) 2018-05-30
ES2330005T5 (es) 2018-06-20
ES2754753T3 (es) 2020-04-20
US20090123941A1 (en) 2009-05-14
EP1616184A2 (en) 2006-01-18
AU2004225472A1 (en) 2004-10-14
EP2360475A1 (en) 2011-08-24
BRPI0408802B1 (pt) 2019-08-20
CN102183656A (zh) 2011-09-14
JP5392980B2 (ja) 2014-01-22

Similar Documents

Publication Publication Date Title
DK1616184T3 (da) Fremgangsmåde og kit til at påvise tidlig begyndelse af renal tubulær cellebeskadigelse
ATE488765T1 (de) Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
AU2002902A (en) Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker
WO2006073682A3 (en) Diagnostic test
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2006116351A3 (en) Method for the early detection of renal disease using proteomics
SE0400191D0 (sv) A test kit for detecting periodontal disease
WO2001042502A3 (en) Methods for disease detection
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
WO2012017466A8 (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
DE60129314D1 (de) Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
FR2816411B1 (fr) Moyens de detection de la transformation pathologique de la proteine app et leurs applications
FR2806739B1 (fr) Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
EP1767652A4 (en) GENMARKER AND ITS USE
DK0507831T3 (da) Fremgangsmåde til detektion af knogle- og bindevævssygdomme hos mennesker og dyr
ITMI20042473A1 (it) Sistema per l'effettuazione di verifiche rapide durante la configurazione delle celle di riferimento flash
ATE433991T1 (de) Morbus-crohn-antikörperepitoppeptid und reagens zum testen auf morbus crohn
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
BR0308095A (pt) Teste para anticorpos anti-ingap
WO2005115394A3 (en) Prenyl-electrostatic switch, and methods of use
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
Porcher et al. Biological markers as indicators of exposure and pneumoconiotic risk: prospective study
DE60115453D1 (de) Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird